Oxford BioDynamics signs new deal to develop predictive biomarkers for IO therapeutics

Image: Oxford BioDynamics will validate potential of EpiSwitch platform in immuno-oncology. Photo: courtesy of dream designs / FreeDigitalPhotos.net.